Definium Therapeutics (DFTX) Research & Development (2021 - 2026)

Definium Therapeutics (DFTX) has reported Research & Development for 6 consecutive years, with $41.5 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Research & Development rose 77.61% year-over-year to $41.5 million; the TTM figure through Mar 2026 stood at $135.8 million (up 76.47% YoY), while the FY2025 annual figure was $117.7 million, up 80.2% from the prior year.
• Research & Development advanced to $41.5 million in Q1 2026 per DFTX's latest filing, from $33.5 million in the prior quarter.
• Across five years, Research & Development topped out at $41.5 million in Q1 2026 and bottomed at $7.8 million in Q3 2022.
• Historically, Research & Development has averaged $18.4 million across 5 years, with a median of $14.6 million in 2024.
• Annual changes were most pronounced in 2022 — Research & Development retreated 18.86% — and 2025, when it surged 103.54%.
• Definium Therapeutics' Research & Development stood at $8.8 million in 2022, then surged by 30.76% to $11.5 million in 2023, then surged by 88.45% to $21.8 million in 2024, then surged by 54.06% to $33.5 million in 2025, then increased by 23.76% to $41.5 million in 2026.
• Business Quant data shows DFTX's Research & Development at $41.5 million in Q1 2026, $33.5 million in Q4 2025, and $31.0 million in Q3 2025.